Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR) bacterial infections and rare diseases in the United States. The company is headquartered in Cambridge, Massachusetts.